Breast cancer: considerable progress in immunotherapy significantly delays life expectancy, even in the worst prognoses
An international study published on July 21 reveals that adding a type of immunotherapy, an antibody called pembrolizumab, to chemotherapy improves the overall survival of patients with advanced triple-negative breast cancer by 27%. worse prognosis in this type of cancer. Triple-negative breast cancer accounts for approximately 15% of all diagnosed breast tumours. Proof of the …